SG11202002533QA - Chimeric polypeptides and uses thereof - Google Patents
Chimeric polypeptides and uses thereofInfo
- Publication number
- SG11202002533QA SG11202002533QA SG11202002533QA SG11202002533QA SG11202002533QA SG 11202002533Q A SG11202002533Q A SG 11202002533QA SG 11202002533Q A SG11202002533Q A SG 11202002533QA SG 11202002533Q A SG11202002533Q A SG 11202002533QA SG 11202002533Q A SG11202002533Q A SG 11202002533QA
- Authority
- SG
- Singapore
- Prior art keywords
- chimeric polypeptides
- chimeric
- polypeptides
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762562223P | 2017-09-22 | 2017-09-22 | |
PCT/US2018/052184 WO2019060695A1 (en) | 2017-09-22 | 2018-09-21 | Chimeric polypeptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002533QA true SG11202002533QA (en) | 2020-04-29 |
Family
ID=63878804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002533QA SG11202002533QA (en) | 2017-09-22 | 2018-09-21 | Chimeric polypeptides and uses thereof |
Country Status (10)
Country | Link |
---|---|
US (3) | US20190092818A1 (en) |
EP (1) | EP3684816A1 (en) |
JP (2) | JP7095078B2 (en) |
KR (2) | KR102483755B1 (en) |
CN (1) | CN111417652B (en) |
AU (2) | AU2018338192B2 (en) |
CA (1) | CA3076099A1 (en) |
IL (1) | IL273327A (en) |
SG (1) | SG11202002533QA (en) |
WO (1) | WO2019060695A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230093066A (en) | 2018-06-01 | 2023-06-26 | 카이트 파마 인코포레이티드 | Chimeric antigen receptor t cell therapy |
CA3127025A1 (en) | 2019-01-18 | 2020-07-23 | Janssen Biotech, Inc. | Gprc5d chimeric antigen receptors and cells expressing the same |
WO2021019389A1 (en) | 2019-07-26 | 2021-02-04 | Janssen Biotech, Inc. | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses |
EP4013783A1 (en) | 2019-08-15 | 2022-06-22 | Janssen Biotech, Inc. | Materials and methods for improved single chain variable fragments |
IL293046A (en) | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof |
IL296263A (en) | 2020-03-13 | 2022-11-01 | Janssen Biotech Inc | Materials and methods for binding siglec-3/cd33 |
AU2021281134A1 (en) | 2020-05-27 | 2023-02-09 | Janssen Biotech, Inc. | Proteins comprising CD3 antigen binding domains and uses thereof |
CA3190307A1 (en) | 2020-07-29 | 2022-02-03 | Janssen Biotech, Inc. | Proteins comprising hla-g antigen binding domains and their uses |
JP2023548034A (en) | 2020-10-22 | 2023-11-15 | ヤンセン バイオテツク,インコーポレーテツド | Proteins containing delta-like ligand 3 (DLL3) antigen-binding domain and uses thereof |
EP4255922A1 (en) | 2020-12-03 | 2023-10-11 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
AR124882A1 (en) | 2021-02-16 | 2023-05-17 | Janssen Pharmaceutica Nv | TRISPECIFIC ANTIBODY DIRECTED TO BCMA, GPRC5D, AND CD3 |
EP4314070A1 (en) | 2021-03-24 | 2024-02-07 | Janssen Biotech, Inc. | Trispecific antibody targeting cd79b, cd20, and cd3 |
JP2024512035A (en) | 2021-03-24 | 2024-03-18 | ヤンセン バイオテツク,インコーポレーテツド | Antibodies targeting CD22 and CD79B |
CA3214307A1 (en) | 2021-03-24 | 2022-09-29 | Janssen Biotech, Inc. | Proteins comprising cd3 antigen binding domains and uses thereof |
BR112023018844A2 (en) | 2021-04-07 | 2023-10-10 | Century Therapeutics Inc | COMPOSITIONS AND METHODS FOR GENERATION OF GAMMA-DELTA T CELLS FROM INDUCED PLURIPOTENT STEM CELLS |
WO2022216524A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Combined artificial cell death/reporter system polypeptide for chimeric antigen receptor cell and uses thereof |
US20220331361A1 (en) | 2021-04-07 | 2022-10-20 | Century Therapeutics, Inc. | Gene transfer vectors and methods of engineering cells |
JP2024513906A (en) | 2021-04-07 | 2024-03-27 | センチュリー セラピューティクス,インコーポレイテッド | Compositions and methods for generating alpha-beta T cells from induced pluripotent stem cells |
EP4334333A1 (en) * | 2021-05-03 | 2024-03-13 | Agilent Technologies, Inc. | Chimeric immunogens and methods for making polyclonal antibodies against specific epitopes |
TW202321311A (en) | 2021-08-02 | 2023-06-01 | 日商諾伊爾免疫生物科技股份有限公司 | Antibody binding to linker of scFv or like |
WO2023046322A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceutica Nv | Proteins comprising cd20 binding domains, and uses thereof |
WO2023129937A1 (en) | 2021-12-29 | 2023-07-06 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
US20230296610A1 (en) | 2022-02-15 | 2023-09-21 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
WO2023192850A1 (en) | 2022-03-29 | 2023-10-05 | Ngm Biopharmaceuticals, Inc. | Ilt3 and cd3 binding agents and methods of use thereof |
WO2023215826A1 (en) | 2022-05-04 | 2023-11-09 | Century Therapeutics, Inc. | Cells engineered with an hla-e and hla-g transgene |
WO2023240147A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Genetically engineered cells expressing cd16 variants and nkg2d and uses thereof |
WO2023240169A1 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof |
WO2023240212A2 (en) | 2022-06-08 | 2023-12-14 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
WO1993019777A1 (en) | 1992-03-30 | 1993-10-14 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
EP0973933A1 (en) * | 1997-02-13 | 2000-01-26 | American National Red Cross | Immunological tolerance to hiv epitopes |
US6897073B2 (en) * | 1998-07-14 | 2005-05-24 | Zyomyx, Inc. | Non-specific binding resistant protein arrays and methods for making the same |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
JP4103267B2 (en) | 1999-10-12 | 2008-06-18 | ソニー株式会社 | headphone |
US6727225B2 (en) * | 1999-12-20 | 2004-04-27 | Immunex Corporation | TWEAK receptor |
IL141023A0 (en) | 2001-01-22 | 2002-02-10 | Gavish Galilee Bio Appl Ltd | Recombinant polypeptides for effective hiv neutralization |
US7056683B2 (en) * | 2002-11-12 | 2006-06-06 | Massachusetts Institute Of Technology | Genetically encoded fluorescent reporters of kinase, methyltransferase, and acetyl-transferase activities |
AU2004213565A1 (en) * | 2003-02-18 | 2004-09-02 | Merck Patent Gmbh | Fusion proteins of interferon alpha muteins with improved properties |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
BRPI0909397A2 (en) * | 2008-03-31 | 2015-12-15 | Glaxo Group Ltd | composition, use of a composition, formulation, delivery device, nucleic acid, vector, host cell, and methods for producing a fusion polypeptide |
JP2013506628A (en) | 2009-09-30 | 2013-02-28 | グラクソ グループ リミテッド | Drug fusions and conjugates with extended half-life |
NZ612512A (en) | 2010-12-09 | 2015-03-27 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
MX2013008376A (en) | 2011-01-18 | 2013-08-12 | Univ Pennsylvania | Compositions and methods for treating cancer. |
US9428565B2 (en) * | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
PT3459560T (en) * | 2011-04-08 | 2021-05-24 | Us Health | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
CN103945861B (en) | 2011-09-12 | 2018-06-05 | 阿穆尼克斯运营公司 | Glucagon-like-peptide-2 composition and its preparation and application |
CA2848410A1 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
US20140072581A1 (en) | 2012-07-23 | 2014-03-13 | Zymeworks Inc. | Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains |
WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
US10450354B2 (en) * | 2013-03-12 | 2019-10-22 | Molecular Templates, Inc. | CD20-binding immunotoxins for inducing cellular internalization and methods using same |
TWI751102B (en) * | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | Antibodies and chimeric antigen receptors specific for cd19 |
AR103442A1 (en) * | 2015-01-16 | 2017-05-10 | Juno Therapeutics Inc | ANTIBODIES AND RECEIVERS OF SPECIFIC CHEMICAL ANTIGENS OF ROR1 |
KR20170110601A (en) * | 2015-02-05 | 2017-10-11 | 몰레큘러 템플레이츠, 인코퍼레이션. | Multivalent CD20 binding molecules comprising a < RTI ID = 0.0 > cigarotoxin A < / RTI > |
ITUB20155272A1 (en) * | 2015-11-02 | 2017-05-02 | Scuola Normale Superiore | Intracellular antibody |
CN106075401A (en) * | 2016-05-31 | 2016-11-09 | 四川大学 | Interleukin-13 5 is preparing the purposes and medicine and IL 35 Fc fusion protein treated in autoimmune skin disease medicine |
US10501775B2 (en) * | 2016-07-12 | 2019-12-10 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
WO2018169922A2 (en) * | 2017-03-13 | 2018-09-20 | Kite Pharma, Inc. | Chimeric antigen receptors for melanoma and uses thereof |
-
2018
- 2018-09-21 EP EP18788941.5A patent/EP3684816A1/en active Pending
- 2018-09-21 KR KR1020207011148A patent/KR102483755B1/en active IP Right Grant
- 2018-09-21 KR KR1020227046061A patent/KR20230007557A/en not_active Application Discontinuation
- 2018-09-21 SG SG11202002533QA patent/SG11202002533QA/en unknown
- 2018-09-21 CN CN201880061651.8A patent/CN111417652B/en active Active
- 2018-09-21 CA CA3076099A patent/CA3076099A1/en active Pending
- 2018-09-21 JP JP2020516415A patent/JP7095078B2/en active Active
- 2018-09-21 US US16/138,331 patent/US20190092818A1/en not_active Abandoned
- 2018-09-21 AU AU2018338192A patent/AU2018338192B2/en active Active
- 2018-09-21 WO PCT/US2018/052184 patent/WO2019060695A1/en unknown
-
2020
- 2020-03-16 IL IL273327A patent/IL273327A/en unknown
- 2020-05-19 US US15/929,737 patent/US11572388B2/en active Active
-
2022
- 2022-03-25 JP JP2022049394A patent/JP2022084852A/en active Pending
- 2022-05-26 AU AU2022203558A patent/AU2022203558A1/en active Pending
- 2022-12-20 US US18/069,151 patent/US20230287054A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102483755B1 (en) | 2023-01-03 |
WO2019060695A1 (en) | 2019-03-28 |
JP2022084852A (en) | 2022-06-07 |
JP7095078B2 (en) | 2022-07-04 |
US20230287054A1 (en) | 2023-09-14 |
AU2022203558A1 (en) | 2022-06-16 |
KR20230007557A (en) | 2023-01-12 |
IL273327A (en) | 2020-04-30 |
AU2018338192A1 (en) | 2020-04-16 |
US11572388B2 (en) | 2023-02-07 |
CA3076099A1 (en) | 2019-03-28 |
CN111417652B (en) | 2023-10-20 |
AU2018338192B2 (en) | 2022-03-03 |
US20200399320A1 (en) | 2020-12-24 |
JP2020534002A (en) | 2020-11-26 |
EP3684816A1 (en) | 2020-07-29 |
KR20200052373A (en) | 2020-05-14 |
CN111417652A (en) | 2020-07-14 |
US20190092818A1 (en) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273327A (en) | Chimeric polypeptides and uses thereof | |
IL275307B (en) | Syntac polypeptides and uses thereof | |
IL282168A (en) | Factor viii chimeric proteins and uses thereof | |
IL269534A (en) | Chimeric molecules and uses thereof | |
IL268346A (en) | Targeted chimeric proteins and uses thereof | |
IL280918A (en) | Multi-chain chimeric polypeptides and uses thereof | |
IL268593A (en) | Polypeptide variants and uses thereof | |
IL280915A (en) | Single-chain chimeric polypeptides and uses thereof | |
IL280808A (en) | Ox40-binding polypeptides and uses thereof | |
ZA201906235B (en) | Csf1r-based chimeric proteins | |
GB201707139D0 (en) | Polypeptides | |
GB201410031D0 (en) | Polypeptides and uses thereof | |
GB201719557D0 (en) | Polypeptide | |
EP3480212C0 (en) | Il13ralpha2 peptide and its uses | |
IL268170A (en) | Vsig8-based chimeric proteins | |
GB201712266D0 (en) | polypeptides and uses thereof | |
GB201712268D0 (en) | Polypeptides and uses thereof | |
GB201812328D0 (en) | Polypeptides and uses thereof | |
GB201613143D0 (en) | Polypeptides and uses thereof | |
GB201613142D0 (en) | Polypeptides and uses thereof | |
GB201717958D0 (en) | Novel polypeptides | |
GB201708471D0 (en) | Polypeptide | |
GB201706915D0 (en) | Novel polypeptides | |
GB201519105D0 (en) | Antibody polypeptides and uses thereof | |
GB201517550D0 (en) | Antibody polypeptides and uses thereof |